“ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adults…
Russia claims a 92 per cent effectiveness for its Sputnik V vaccine candidate, which is being tested on humans in mid- to late-stage trials by Hyderabad-based Dr Reddy’s Laboratories in India.
The success rates of the shots are way above WHO recommendations, which mandates that successful vaccines should show disease risk reduction of at least 50 per cent.
Availability: Serum Institute of India, which is conducting Phase III trials of the vaccine in India, said the Oxford vaccine (named Covishield in India) should be available for healthcare workers and elderly people by around February 2021 and by April for the general public.
SII CEO Adar Poonawalla said 30-40 crore doses of the vaccine will be available by the first quarter of 2021. The Pune-based firm is likely to apply to India’s drug regulator next month for emergency approval.
Side-effects: So far, no major complaints, reactions or adverse events have been reported in Indian arm of the trials.
The Lancet study mentions that adverse reactions to the vaccine were mild, with the most common effects being injection-site pain and tenderness, fatigue, headache, feverishness and muscle pain.
Price: Serum Institute said the vaccine, which can be stored at temperatures between 2°C and 8°C, will cost £3 per dose for the general public. In other parts, it is likely to cost under £3 a dose.
Don’t miss from Explained | New study throws light on long-distance airborne dispersal of SARS-CoV-2
Read more: https://khabrennews.com/?p=1762